Cite
HARVARD Citation
Huang, C. et al. (n.d.). 1OTrastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study. Annals of oncology. p. . [Online].